ИНГИБИТОРЫ ФОСФОДИЭСТЕРАЗЫ-4: НОВЫЕ ПЕРСПЕКТИВЫ ПРОТИВОВОСПАЛИТЕЛЬНОЙ ТЕРАПИИ ХОБЛ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Рофлумиласт является первым и пока единственным ингибитором фосфодиэстеразы-4 (ФДЭ-4), зарегистрированным в качестве дополнительной терапии пациентов с тяжелой хронической обструктивной болезнью легких (ХОБЛ) и частыми обострениями, уже получающими терапию длительно действующими бронходилататорами. Основной механизм действия рофлумиласта связан с угнетением воспаления дыхательных путей у пациентов с ХОБЛ. В клинических исследованиях 3-й фазы показано, что рофлумиласт приводит к улучшению функциональных параметров, симптомов, качества жизни и снижению числа обострений ХОБЛ.

Полный текст

Доступ закрыт

Об авторах

С. Н Авдеев

НИИ пульмонологии ФМБА России

профессор Москва

Список литературы

  1. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007;4:112.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2013. www. goldcopd.org/. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
  3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50.
  4. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16.
  5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 19902020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
  6. Stanford RH, Shen Y, McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 2006;5:343-49.
  7. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
  8. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;151:1418-22.
  9. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-57.
  10. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22:672-88.
  11. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
  12. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
  13. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54:245-52.
  14. Meshi B, Vitalis TZ, Ionescu D, et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002;26:52-7.
  15. Gilmour PS, Rahman I, Hayashi S, et al. Adenoviral E1A primes alveolar epithelial cells to PM(10)-induced transcription of interleukin-8. Am J Physiol Lung Cell Mol Physiol 2001;281:L598-606.
  16. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1b-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-903.
  17. Ito K, Lim S, Caramori G, et al. Cigarette smok ing reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits gluco-corticoid actions in alveolar macrophages. FASEB J 2001;15:1100-102.
  18. Barnes PJ. Macrophages as orchestrators of COPD. J COPD 2004;1:59-70.
  19. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004;59:992-96.
  20. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-309.
  21. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
  22. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumour necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-34.
  23. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-48.
  24. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155:449-53.
  25. Peleman RA, Rytila PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999;13:839-43.
  26. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Resp Crit Care Med 1995;152:1666-72.
  27. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T-lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-57.
  28. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997;156:1633-39.
  29. O'Shaughnessy TC, Ansari TW, Barnes NC. Inflammatory cells in the airway surface epithelium of smokers with and without bronchitic airflow obstruction. Eur Respir J 1996;9(Suppl. 23):14s.
  30. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
  31. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152:1262-67.
  32. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12-8.
  33. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121(Suppl. 5):151-55.
  34. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56:515-48.
  35. Di Stefano A, Maestrelli P, Roggeri A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994;149:803-10.
  36. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-48.
  37. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-39.
  38. Loppow D, Schleiss MB, Kanniess F, et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:115-21.
  39. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005;5:3.
  40. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165: 1592-96.
  41. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-43.
  42. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009 151 517-27.
  43. Barnes NC, Qiu Y-S, Pavord ID, et al. Antiinflammatory effects of salmeterol/ fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43.
  44. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63.
  45. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352: 1967-76.
  46. Antoniu S.A. New therapeutic options in the management of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011;6:147-55.
  47. Tenor H HA, Beume R, Lahu G, Zech K, Bethke T. Pharmacology, clinical efficacy and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. In: Francis SH, et al. (eds). In "Phosphodiesterases as drug targets, handbook of experimental pharmacology 204". Berlin Heidelberg: Springer-Verlag; 2011.
  48. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D. Steroid insensitivity in a short-term model of cigarette smoke induced pulmonary inflammation in mice. Am J Respir Crit Care Med 2008; 177:A651.
  49. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D. Therapeutic effect of various PDE4 inhibitors on cigarette smoke induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 2008;177:A652.
  50. Bethke TD, Bohmer GM, Hermann R, et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007;47:26-36.
  51. Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther 2011;49:51-7.
  52. Grootendorst DC, Gauw SA, Verhoosel RM, et al. The PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Thorax 2007;62:1081-87.
  53. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005;366:563-71.
  54. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61.
  55. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with lon-gacting bronchodilators: two randomised clinical trials. Lancet 2009;374 695-703.
  56. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
  57. Rennard SI, Calverley PMA, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respiratory Research 2011,12:18.
  58. Bateman ED, Rabe KF, Calverley PMA, et al. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011;38:553-60
  59. Rice JP, Saccone NL, Rasmussen E. Definition of the phenotype. Adv Genet 2001;42:69-76.
  60. Han MK, Agusti A, Calverley PM, et al. COPD phenotypes: The future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
  61. Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol 2011;28:107-29.
  62. Rabe KF. Update on roflumilast, a phosphodi esterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.
  63. FDA. Centre for Drug Evaluation and Research. Application number 022522Orig1s000. Medical Review(s). Available at http://wwwaccessdatafdagov /drugsatfda_docs/nda/2011/0 22522Orig1s000MedRpdf.
  64. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-82.
  65. Wouters EF, Bredenbrker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:1720-25.
  66. Wouters EFM, Teichmann P, Brose M, et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on glucose homeostasis in patients with treatment-naive diabetes (type 2). Am J Respir Crit Care Med 2010;181:4471.
  67. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23:235- 56.
  68. Daliresp. Full prescribing information, revised September 2011. Forest Pharmaceuticals, St Louis. 2011.
  69. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011;12:140.
  70. Wedzicha JA, Rabe KF, Martinez FJ, et al. Roflumilast for the frequent exacerbator phe-notype.Chest 2013; 143: online first. http:// journal.publications.chestnet.org/

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах